The clinical diagnosis of myocardial infarction (MI) relies on symptoms, electrocardiographic findings, and biochemical markers (troponin, serum creatine kinase, creatine kinase‐MB).1,2 Acute ischaemic syndromes are now classified as unstable angina/non‐ST‐elevation MI (UA/NSTEMI) and acute ischaemic syndromes with ST‐elevation MI (STEMI).1,2 The new diagnostic criteria and markers are leading to increased proportions3 of acute ischaemic syndromes being recognised as acute MI. Obviously, elevated troponin concentrations are not, by themselves, synonymous with acute MI and can occur in a variety of cardiac and non‐cardiac disorders (for example, sepsis or septic shock, pulmonary embolism, acute exacerbation of chronic obstructive pulmonary disease).4 Therefore, the diagnosis of acute MI relies on the combination of all clinical and biochemical tools, each providing its own diagnostic contribution.